Evotec Se - Adr (EVO)

$5.1

-0.13

(-2.49%)▲

Market is closed - opens 7 PM, 26 Apr 2024

Insights on Evotec Se - Adr

  • Increasing Revenue

    Revenue is up for the last 2 quarters, 170.27M → 196.27M (in $), with an average increase of 13.3% per quarter

  • Decreasing Net Profit

    Netprofit is down for the last 2 quarters, -14.92M → -38.95M (in $), with an average decrease of 160.9% per quarter

  • Vs NBIX

    In the last 1 year, Neurocrine Biosciences Inc. has given 34.1% return, outperforming this stock by 77.6%

Performance

  • $4.88
    $5.10
    $5.10
    downward going graph

    4.29%

    Downside

    Day's Volatility :4.29%

    Upside

    0.0%

    downward going graph
  • $4.87
    $13.49
    $5.10
    downward going graph

    4.51%

    Downside

    52 Weeks Volatility :63.9%

    Upside

    62.19%

    downward going graph

Returns

PeriodEvotec Se - AdrSector (Health Care)Index (Russel 2000)
3 Months
-35.44%
0.5%
0.0%
6 Months
-42.83%
11.7%
0.0%
1 Year
-43.52%
6.2%
2.2%
3 Years
-76.82%
13.5%
-23.0%

Highlights

Market Capitalization
1.9B
Book Value
$6.45
Earnings Per Share (EPS)
-0.28
Wall Street Target Price
15.6
Profit Margin
-11.57%
Operating Margin TTM
-6.2%
Return On Assets TTM
0.17%
Return On Equity TTM
-8.02%
Revenue TTM
820.8M
Revenue Per Share TTM
2.32
Quarterly Revenue Growth YOY
12.9%
Gross Profit TTM
151.5M
EBITDA
97.3M
Diluted Eps TTM
-0.28
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
-0.35
EPS Estimate Next Year
0.11
EPS Estimate Current Quarter
-0.05
EPS Estimate Next Quarter
0.02

Analyst Recommendation

Buy
    87%Buy
    12%Hold
    0
    0%Sell
Based on 16 Wall street analysts offering stock ratings for Evotec Se - Adr(by analysts ranked 0 to 5 stars)
Based on 16 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
14
15
15
Hold
2
2
2
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 205.88%

Current $5.10
Target $15.60

Company Financials

FY18Y/Y Change
Revenue
429.5M
↑ 45.71%
Net Income
96.3M
↑ 247.0%
Net Profit Margin
22.42%
↑ 13.0%
FY19Y/Y Change
Revenue
500.1M
↑ 18.92%
Net Income
42.6M
↓ 54.77%
Net Profit Margin
8.53%
↓ 13.89%
FY20Y/Y Change
Revenue
616.1M
↑ 12.2%
Net Income
7.7M
↓ 83.51%
Net Profit Margin
1.25%
↓ 7.28%
FY21Y/Y Change
Revenue
699.9M
↑ 23.38%
Net Income
244.1M
↑ 3332.78%
Net Profit Margin
34.87%
↑ 33.62%
FY22Y/Y Change
Revenue
805.0M
↑ 21.59%
Net Income
-188.2M
↓ 181.51%
Net Profit Margin
-23.38%
↓ 58.25%
FY23Y/Y Change
Revenue
820.8M
↑ 9.23%
Net Income
-95.0M
↓ 45.93%
Net Profit Margin
-11.57%
↑ 11.81%
Q2 FY22Q/Q Change
Revenue
179.9M
↓ 7.95%
Net Income
-29.2M
↓ 11.25%
Net Profit Margin
-16.22%
↑ 0.61%
Q3 FY22Q/Q Change
Revenue
170.9M
↑ 0.98%
Net Income
-46.5M
↑ 69.22%
Net Profit Margin
-27.19%
↓ 10.97%
Q4 FY22Q/Q Change
Revenue
257.8M
↑ 38.42%
Net Income
-29.1M
↓ 42.46%
Net Profit Margin
-11.3%
↑ 15.89%
Q1 FY23Q/Q Change
Revenue
262.5M
↑ 0.0%
Net Income
-29.7M
↑ 0.0%
Net Profit Margin
-11.3%
↑ 0.0%
Q2 FY23Q/Q Change
Revenue
185.8M
↓ 29.25%
Net Income
-16.3M
↓ 45.12%
Net Profit Margin
-8.77%
↑ 2.53%
Q3 FY23Q/Q Change
Revenue
196.3M
↑ 15.27%
Net Income
-39.0M
↑ 160.94%
Net Profit Margin
-19.85%
↓ 11.08%
FY17Y/Y Change
Total Assets
667.3M
↑ 89.91%
Total Liabilities
335.5M
↑ 144.14%
FY18Y/Y Change
Total Assets
883.1M
↑ 15.68%
Total Liabilities
397.0M
↑ 3.42%
FY19Y/Y Change
Total Assets
1.3B
↑ 52.99%
Total Liabilities
788.5M
↑ 102.85%
FY20Y/Y Change
Total Assets
1.8B
↑ 23.88%
Total Liabilities
910.3M
↑ 5.14%
FY21Y/Y Change
Total Assets
2.5B
↑ 52.79%
Total Liabilities
971.1M
↑ 15.87%
FY22Y/Y Change
Total Assets
2.4B
↑ 0.99%
Total Liabilities
1.1B
↑ 24.79%
Q2 FY22Q/Q Change
Total Assets
2.4B
↑ 2.62%
Total Liabilities
1.1B
↑ 18.74%
Q3 FY22Q/Q Change
Total Assets
2.2B
↓ 1.35%
Total Liabilities
1.0B
↑ 1.57%
Q4 FY22Q/Q Change
Total Assets
2.4B
↓ 0.24%
Total Liabilities
1.1B
↑ 3.47%
Q1 FY23Q/Q Change
Total Assets
2.5B
↑ 0.0%
Total Liabilities
1.2B
↑ 0.0%
Q2 FY23Q/Q Change
Total Assets
2.5B
↑ 1.95%
Total Liabilities
1.2B
↑ 5.31%
Q3 FY23Q/Q Change
Total Assets
2.3B
↓ 2.03%
Total Liabilities
1.1B
↓ 1.18%
FY18Y/Y Change
Operating Cash Flow
178.7M
↑ 1342.93%
Investing Cash Flow
-44.8M
↓ 85.46%
Financing Cash Flow
-89.0M
↓ 132.3%
FY19Y/Y Change
Operating Cash Flow
47.3M
↓ 72.98%
Investing Cash Flow
-97.0M
↑ 121.4%
Financing Cash Flow
236.7M
↓ 371.67%
FY20Y/Y Change
Operating Cash Flow
55.0M
↑ 5.93%
Investing Cash Flow
-190.8M
↑ 79.02%
Financing Cash Flow
303.1M
↑ 16.64%
FY21Y/Y Change
Operating Cash Flow
138.4M
↑ 173.33%
Investing Cash Flow
-276.2M
↑ 57.24%
Financing Cash Flow
451.2M
↑ 61.69%
Q2 FY22Q/Q Change
Operating Cash Flow
184.9M
↑ 193.34%
Investing Cash Flow
-116.1M
↑ 16.08%
Financing Cash Flow
-42.3M
↓ 109.99%
Q3 FY22Q/Q Change
Operating Cash Flow
-3.9M
↓ 102.25%
Investing Cash Flow
-224.3M
↑ 105.33%
Financing Cash Flow
-4.6M
↓ 88.53%
Q4 FY22Q/Q Change
Operating Cash Flow
-35.9M
↑ 743.66%
Investing Cash Flow
15.4M
↓ 106.31%
Financing Cash Flow
-2.1M
↓ 57.84%
Q1 FY23Q/Q Change
Operating Cash Flow
-36.6M
↑ 0.0%
Investing Cash Flow
15.7M
↑ 0.0%
Financing Cash Flow
-2.1M
↑ 0.0%
Q2 FY23Q/Q Change
Operating Cash Flow
-3.0M
↓ 91.69%
Investing Cash Flow
15.7M
↑ 0.0%
Financing Cash Flow
5.7M
↓ 367.35%
Q3 FY23Q/Q Change
Operating Cash Flow
20.8M
↓ 844.72%
Investing Cash Flow
-15.8M
↓ 209.48%
Financing Cash Flow
43.4M
↑ 727.63%

Technicals Summary

Sell

Neutral

Buy

Evotec Se - Adr is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.

More on Technical Analysis

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Evotec Se - Adr
Evotec Se - Adr
-31.54%
-42.83%
-43.52%
-76.82%
-76.82%
Neurocrine Biosciences Inc.
Neurocrine Biosciences Inc.
-2.41%
27.65%
34.11%
39.49%
77.94%
Haleon Plc Spon Ads
Haleon Plc Spon Ads
-0.12%
5.13%
-5.51%
13.36%
13.36%
Zoetis Inc.
Zoetis Inc.
-7.43%
-2.98%
-11.32%
-9.68%
48.39%
Viatris Inc.
Viatris Inc.
-1.12%
27.59%
26.04%
-15.35%
-29.8%
Catalent, Inc.
Catalent, Inc.
-0.82%
42.09%
27.6%
-51.77%
23.97%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Evotec Se - Adr
Evotec Se - Adr
485.75
NA
NA
-0.35
-0.08
0.0
NA
6.45
Neurocrine Biosciences Inc.
Neurocrine Biosciences Inc.
56.26
56.26
0.44
4.78
0.13
0.09
NA
22.61
Haleon Plc Spon Ads
Haleon Plc Spon Ads
29.82
29.82
1.69
0.45
0.07
0.04
0.03
1.8
Zoetis Inc.
Zoetis Inc.
29.5
29.5
2.58
5.8
0.5
0.13
0.01
10.9
Viatris Inc.
Viatris Inc.
231.0
231.0
NA
2.78
0.0
0.03
0.04
17.05
Catalent, Inc.
Catalent, Inc.
211.02
NA
2.06
0.48
-0.3
-0.01
NA
20.41
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Evotec Se - Adr
Evotec Se - Adr
Buy
$1.9B
-76.82%
485.75
-11.57%
Neurocrine Biosciences Inc.
Neurocrine Biosciences Inc.
Buy
$14.1B
77.94%
56.26
13.23%
Haleon Plc Spon Ads
Haleon Plc Spon Ads
Buy
$38.1B
13.36%
29.82
9.28%
Zoetis Inc.
Zoetis Inc.
Buy
$68.3B
48.39%
29.5
27.43%
Viatris Inc.
Viatris Inc.
Hold
$13.7B
-29.8%
231.0
0.35%
Catalent, Inc.
Catalent, Inc.
Hold
$10.1B
23.97%
211.02
-31.77%

Institutional Holdings

  • Mubadala Investment Company PJSC

    1.30%

  • Federated Hermes Inc

    0.16%

  • Zurcher Kantonalbank

    0.05%

  • Millennium Management LLC

    0.02%

  • Optiver Holding B.V.

    0.02%

  • DCF Advisers, LLC

    0.01%

Corporate Announcements

  • Evotec Se - Adr Dividends March,2019

    In the quarter ending March,2019. Evotec Se - Adr has declared dividend of $0.07

    Read More

Company Information

Evotec SE is a publicly listed drug discovery and development company headquartered in Hamburg, Germany. The company operates globally, largely through external alliances with pharmaceutical and biotechnology companies, academic institutions, patient advocacy groups, and venture capitalists.

Organization
Evotec Se - Adr
Employees
5061
CEO
Dr. Mario Polywka DPHIL, Ph.D.
Industry
Miscellaneous

Discover More

FAQs